Format

Send to

Choose Destination
Nutrients. 2015 Mar 31;7(4):2261-73. doi: 10.3390/nu7042261.

The role of omega-3 fatty acids in acute pancreatitis: a meta-analysis of randomized controlled trials.

Author information

1
Graduate School, Southern Medical University, Guangzhou 510515, China. lqiuchenggd@163.com.
2
Department of General Surgery, Jinling Hospital, Clinical College of Southern Medical University, Nanjing 210002, China. lqiuchenggd@163.com.
3
Graduate School, Southern Medical University, Guangzhou 510515, China. MG1335118@smail.nju.edu.cn.
4
Department of General Surgery, Jinling Hospital, Clinical College of Southern Medical University, Nanjing 210002, China. MG1335118@smail.nju.edu.cn.
5
Research Institute of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China. MG1335118@smail.nju.edu.cn.
6
Department of Surgery, Prince of Wales Hospital, Faculty of Medicine, the Chinese University of Hong Kong, Hong Kong 999077, China. xiaxianf@gmail.com.
7
Key Laboratory for Medical Molecular Diagnostics of Guangdong Province, Guangdong Medical College, Dongguan 523808, China. zhenghzgd@163.com.
8
Research Institute of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China. ahbijingcheng@163.com.
9
Research Institute of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China. easyhard666@163.com.
10
Research Institute of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China. liningnju@163.com.

Abstract

To determine whether treatment with omega-3 fatty acids (ω-3 FA) provides benefits to patients with acute pancreatitis (AP). The Cochrane Library, PubMed, Embase, Web of Science, and Chinese Biomedical Literature Database were searched. Data analysis was performed using Revman 5.2 software. A total of eight randomized controlled trials (RCTs) were included. Overall, ω-3 FA treatment resulted in a significantly reduced risk of mortality (RR 0.35; 95% CI 0.16 to 0.75, p < 0.05), infectious complications (RR 0.54; 95% CI 0.34 to 0.85, p < 0.05) and length of hospital stay (MD -6.50; 95% CI -9.54 to -3.46, p < 0.05), but not length of ICU stay (MD -1.98; 95% CI -6.92 to 2.96, p > 0.05). In subgroup analysis, only patients who received ω-3 FA parenterally had some statistically significant benefits in terms of mortality (risk ratio (RR) 0.37; 95% confidence interval (CI) 0.16 to 0.86, p < 0.05), infectious complications (RR 0.5; 95% CI 0.28 to 0.9, p < 0.05) and length of hospital stay (mean difference (MD) -8.13; 95% CI -10.39 to -5.87, p < 0.001). The administration of ω-3 FA may be beneficial for decreasing mortality, infectious complications, and length of hospital stay in AP, especially when used parenterally. Large and rigorously designed RCTs are required to elucidate the efficacy of parenteral or enteral ω-3 FA treatment in AP.

PMID:
25835048
PMCID:
PMC4425143
DOI:
10.3390/nu7042261
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center